Yes, Lupron (leuprolide acetate) is FDA-approved and commonly used to treat central precocious puberty (CPP) in children.[1][2]
How Lupron treats CPP
Lupron is a gonadotropin-releasing hormone (GnRH) agonist that suppresses pituitary gonadotropin secretion after initial stimulation. In CPP—where the pituitary gland prematurely triggers puberty, causing early breast development, pubic hair, or menstruation—Lupron halts sex hormone production, delaying bone age advancement and preserving adult height potential. It's given as monthly or 3- or 6-month depot injections.[1][3]
Who qualifies for treatment
Treatment targets children with confirmed CPP via GnRH stimulation test, typically girls under 8 and boys under 9. Guidelines from the Pediatric Endocrine Society endorse GnRH agonists like Lupron as first-line therapy when progression risks height loss or psychosocial issues.[2][4]
Common dosing and monitoring
Doses start at 0.3 mg/kg monthly (max 7.5 mg) or higher for longer-acting forms, adjusted by response. Doctors monitor with height checks, bone age X-rays, and hormone levels every 6-12 months; therapy stops at age-appropriate puberty onset.[1][3]
Side effects patients report
Injection-site pain, hot flashes, and mood changes occur initially. Rare risks include sterile abscesses or anaphylaxis. Long-term data show no major fertility impacts post-treatment.[2][5]
Alternatives to Lupron
Other GnRH agonists like triptorelin (Trelstar) or histrelin implants (Supprelin LA) work similarly. No oral options exist; choice depends on dosing preference and insurance.[4]
Treatment duration and outcomes
Most kids receive 2-4 years until physiologic puberty. Studies report 90%+ achieve target adult height.[2][3]
[1]: Lupron Depot-Ped FDA Label
[2]: Pediatric Endocrine Society CPP Guidelines
[3]: DrugPatentWatch.com - Lupron Patents
[4]: AAP CPP Management
[5]: Long-term Lupron Safety Review